Literature DB >> 30610566

The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.

Rovshan Hasanov1, Berna İmge Aydoğan2, Saba Kiremitçi3, Esra Erden3, Sevim Güllü1.   

Abstract

The fourth edition of the World Health Organization (WHO) classification of pituitary tumors recommended evaluation of tumor proliferation and invasion to identify aggressiveness. We aimed to assess the prognostic roles of the Ki-67 proliferation index, mitotic index, P53 expression, and cavernous sinus invasion in pituitary adenomas (PAs). Among the 601 patients who underwent transnasal/transsphenoidal adenomectomy from 2001 to 2016, 101 patients (16.8%) who had tumors with a high (≥ 3%) Ki-67 index (group A) and a control group consisting of 43 patients with a low (< 3%) Ki 67 index who were matched for age, gender, and tumor type were included. Mitotic index and P53 expressions were evaluated. Patient characteristics, histopathology reports, pre/postoperative magnetic resonance imaging (MRI), and follow-up data were assessed retrospectively. The frequency of macroadenomas and mean tumor size were greater in group A when compared to group B (67.4 vs. 94.1%, p< 0.01 and 25 ± 10.6 vs. 18 ± 11 mm, p< 0.01, respectively). Invasion to cavernous sinus was found in 53 (36.8%) patients and was more frequent in group A (p<0.01). The mean number of surgery was higher in group A than group B (p< 0.05). The mean follow-up period was 46.6 ± 34 months. The postoperative MRIs and follow-up data for at least 24 months were available in 117 patients. Recurrence risk was higher in group A than group B (p = 0.03). Tumors with high Ki-67 proliferation index were grouped as 3-5, 6-10, 11-15, and > 15%. The risk of recurrence was not different between groups of high Ki-67 index. The optimal cutoff point of the Ki-67 proliferation index that predicted recurrence was 2.5% with 84.6% sensitivity and 47.4% specificity. The cavernous sinus invasion on MRI was associated with recurrence (p = 0.03). Tumor size and recurrence risk were not associated with P53 expression. High P53 expression was related with cavernous sinus invasion (p = 0.03). The mitotic index was not associated with recurrence risk and tumor invasion. Recurrence risk was higher in tumors with ≥ 2 histopathological atypia criteria (p = 0.01). High Ki-67 index with a 2.5% cutoff point and cavernous sinus invasion on MRI are reliable markers for predicting recurrence in PAs. Recurrence risk is also higher in tumors with two histopathological aggressiveness criteria. Strict follow-up and more aggressive treatment approaches may be necessary for invasive-proliferative PAs.

Entities:  

Keywords:  Cavernous sinus invasion; Ki-67; Mitotic index; P53; Pituitary adenoma; Recurrence risk

Mesh:

Substances:

Year:  2019        PMID: 30610566     DOI: 10.1007/s12022-018-9563-2

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  12 in total

1.  Initial Gamma Knife radiosurgery for nonfunctioning pituitary adenomas: results from a 26-year experience.

Authors:  Jinxiu Yu; Yanli Li; Tingting Quan; Xi Li; Chao Peng; Jiamin Zeng; Shunyao Liang; Minyi Huang; Yong He; Yinhui Deng
Journal:  Endocrine       Date:  2020-03-11       Impact factor: 3.633

2.  MGMT immunohistochemistry in pituitary tumors: controversies with clinical implications.

Authors:  George Kontogeorgos; Eleni Thodou; Mary Koutourousiou; Gregory Kaltsas; Andreas Seretis
Journal:  Pituitary       Date:  2019-12       Impact factor: 4.107

3.  K i -67/MIB-1 and Recurrence in Pituitary Adenoma.

Authors:  Kent Tadokoro; Colten Wolf; Joseph Toth; Cara Joyce; Meharvan Singh; Anand Germanwala; Chirag Patel
Journal:  J Neurol Surg B Skull Base       Date:  2021-09-21

4.  Classifying Pituitary Adenoma Invasiveness Based on Radiological, Surgical and Histological Features: A Retrospective Assessment of 903 Cases.

Authors:  Liang Lu; Xueyan Wan; Yu Xu; Juan Chen; Kai Shu; Ting Lei
Journal:  J Clin Med       Date:  2022-04-27       Impact factor: 4.964

5.  Cell proliferation, apoptosis, and angiogenesis in non-functional pituitary adenoma: association with tumor invasiveness.

Authors:  Maliheh Ghadir; Mohammad E Khamseh; Mahshid Panahi-Shamsabad; Mohammad Ghorbani; Hamideh Akbari; Ali Zare Mehrjardi; Maryam Honardoost; Bahram Jafar-Mohammadi
Journal:  Endocrine       Date:  2020-07-12       Impact factor: 3.633

6.  Plurihormonal PIT-1-Positive Pituitary Adenomas: A Systematic Review and Single-Center Series.

Authors:  John P Andrews; Rushikesh S Joshi; Matheus P Pereira; Taemin Oh; Alexander F Haddad; Kaitlyn M Pereira; Robert C Osorio; Kevin C Donohue; Zain Peeran; Sweta Sudhir; Saket Jain; Angad Beniwal; Ashley S Chopra; Narpal S Sandhu; Tarik Tihan; Lewis Blevins; Manish K Aghi
Journal:  World Neurosurg       Date:  2021-04-20       Impact factor: 2.210

7.  Identifying critical protein-coding genes and long non-coding RNAs in non-functioning pituitary adenoma recurrence.

Authors:  Jing Guo; Qiuyue Fang; Yulou Liu; Weiyan Xie; Yazhuo Zhang; Chuzhong Li
Journal:  Oncol Lett       Date:  2021-02-08       Impact factor: 2.967

8.  The effect of hypoxia on the proliferation capacity of dermal papilla cell by regulating lactate dehydrogenase.

Authors:  Jun Ye; Xiaoli Tang; Yunzhu Long; Zhou Chu; Qing Zhou; Bojie Lin
Journal:  J Cosmet Dermatol       Date:  2020-07-17       Impact factor: 2.696

9.  Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas.

Authors:  Liza Das; Nidhi Gupta; Pinaki Dutta; Rama Walia; Kim Vaiphei; Ashutosh Rai; Bishan Dass Radotra; Kirti Gupta; Sreejesh Sreedharanunni; Chirag Kamal Ahuja; Anil Bhansali; Manjul Tripathi; Ridhi Sood; Sivashanmugam Dhandapani
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-17       Impact factor: 5.555

10.  A Nomogram for Preoperatively Predicting the Ki-67 Index of a Pituitary Tumor: A Retrospective Cohort Study.

Authors:  Xiangming Cai; Junhao Zhu; Jin Yang; Chao Tang; Feng Yuan; Zixiang Cong; Chiyuan Ma
Journal:  Front Oncol       Date:  2021-05-31       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.